These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 28199769)
1. Protein-Templated Formation of an Inhibitor of the Blood Coagulation Factor Xa through a Background-Free Amidation Reaction. Jaegle M; Steinmetzer T; Rademann J Angew Chem Int Ed Engl; 2017 Mar; 56(13):3718-3722. PubMed ID: 28199769 [TBL] [Abstract][Full Text] [Related]
3. Identification of anthranilamide derivatives as potential factor Xa inhibitors: drug design, synthesis and biological evaluation. Xing J; Yang L; Li H; Li Q; Zhao L; Wang X; Zhang Y; Zhou M; Zhou J; Zhang H Eur J Med Chem; 2015 May; 95():388-99. PubMed ID: 25839438 [TBL] [Abstract][Full Text] [Related]
4. Semisynthesis of ent-norstrobane diterpenoids as potential inhibitor for factor Xa. Wang J; Ma H; Fu H Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3813-3815. PubMed ID: 30340898 [TBL] [Abstract][Full Text] [Related]
5. The Development of New Factor Xa Inhibitors Based on Amide Synthesis. Tarasov DN; Tovbin DG; Malakhov DV; Aybush AV; Tserkovnikova NA; Savelyeva MI; Sychev DA; Drozd NN; Savchenko AY Curr Drug Discov Technol; 2018; 15(4):335-350. PubMed ID: 29468977 [TBL] [Abstract][Full Text] [Related]
6. Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors. Verhoef D; Visscher KM; Vosmeer CR; Cheung KL; Reitsma PH; Geerke DP; Bos MHA Nat Commun; 2017 Sep; 8(1):528. PubMed ID: 28904343 [TBL] [Abstract][Full Text] [Related]
7. Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation. Wang W; Yuan J; Fu X; Meng F; Zhang S; Xu W; Xu Y; Huang C Molecules; 2016 Apr; 21(4):491. PubMed ID: 27089317 [TBL] [Abstract][Full Text] [Related]
8. Molecular modeling studies of [6,6,5] Tricyclic Fused Oxazolidinones as FXa inhibitors using 3D-QSAR, Topomer CoMFA, molecular docking and molecular dynamics simulations. Xu C; Ren Y Bioorg Med Chem Lett; 2015 Oct; 25(20):4522-8. PubMed ID: 26343829 [TBL] [Abstract][Full Text] [Related]
9. The design of phenylglycine containing benzamidine carboxamides as potent and selective inhibitors of factor Xa. Jones SD; Liebeschuetz JW; Morgan PJ; Murray CW; Rimmer AD; Roscoe JM; Waszkowycz B; Welsh PM; Wylie WA; Young SC; Martin H; Mahler J; Brady L; Wilkinson K Bioorg Med Chem Lett; 2001 Mar; 11(5):733-6. PubMed ID: 11266180 [TBL] [Abstract][Full Text] [Related]
10. Synthesis of 3,4-diaminobenzoyl derivatives as factor Xa inhibitors. Yang J; Su G; Ren Y; Chen Y Eur J Med Chem; 2015 Aug; 101():41-51. PubMed ID: 26114810 [TBL] [Abstract][Full Text] [Related]
11. NMR structure determination of Ixolaris and factor X(a) interaction reveals a noncanonical mechanism of Kunitz inhibition. De Paula VS; Sgourakis NG; Francischetti IMB; Almeida FCL; Monteiro RQ; Valente AP Blood; 2019 Aug; 134(8):699-708. PubMed ID: 31133602 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and structure-activity relationship of oxazolidinone derivatives containing novel S4 ligand as FXa inhibitors. Zhao Y; Jiang M; Zhou S; Wu S; Zhang X; Ma L; Zhang K; Gong P Eur J Med Chem; 2015; 96():369-80. PubMed ID: 25911624 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and discovery of 1-(2-(6-Chloro-3-methylsulfonyl)-naphthyl)-1H-pyrazole-5-carboxylamides as highly potent factor Xa inhibitors. Jia ZJ; Scarborough RM; Zhang P; Halfon S; Arfsten AE; Sinha U; Zhu BY Chem Pharm Bull (Tokyo); 2009 Sep; 57(9):1004-7. PubMed ID: 19721266 [TBL] [Abstract][Full Text] [Related]
14. Understanding protein-ligand interactions: the price of protein flexibility. Rauh D; Klebe G; Stubbs MT J Mol Biol; 2004 Jan; 335(5):1325-41. PubMed ID: 14729347 [TBL] [Abstract][Full Text] [Related]
15. Novel FXa Inhibitor Identification through Integration of Ligand- and Structure-Based Approaches. Lagos CF; Segovia GF; Nuñez-Navarro N; Faúndez MA; Zacconi FC Molecules; 2017 Sep; 22(10):. PubMed ID: 28937618 [TBL] [Abstract][Full Text] [Related]
16. Synthesis, Docking, and In Vitro Anticoagulant Activity Assay of Hybrid Derivatives of Pyrrolo[3,2,1- Novichikhina N; Ilin I; Tashchilova A; Sulimov A; Kutov D; Ledenyova I; Krysin M; Shikhaliev K; Gantseva A; Gantseva E; Podoplelova N; Sulimov V Molecules; 2020 Apr; 25(8):. PubMed ID: 32325823 [TBL] [Abstract][Full Text] [Related]
17. Identification of potent orally active factor Xa inhibitors based on conjugation strategy and application of predictable fragment recommender system. Ishihara T; Koga Y; Iwatsuki Y; Hirayama F Bioorg Med Chem; 2015 Jan; 23(2):277-89. PubMed ID: 25523211 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and SAR of benzamidine factor Xa inhibitors containing a vicinally-substituted heterocyclic core. Fevig JM; Pinto DJ; Han Q; Quan ML; Pruitt JR; Jacobson IC; Galemmo RA; Wang S; Orwat MJ; Bostrom LL; Knabb RM; Wong PC; Lam PYS ; Wexler RR Bioorg Med Chem Lett; 2001 Mar; 11(5):641-5. PubMed ID: 11266160 [TBL] [Abstract][Full Text] [Related]
19. Investigation of the tight binding mechanism of a new anticoagulant DD217 to factor Xa by means of molecular docking and molecular dynamics. Shulga DA; Tserkovnikova NA; Tarasov DN; Tovbin DG J Biomol Struct Dyn; 2023 Jul; 41(10):4723-4734. PubMed ID: 35532097 [TBL] [Abstract][Full Text] [Related]
20. Degradation of a benzamidine-type synthetic inhibitor of coagulation enzymes in plasma of various species. Hauptmann J Thromb Res; 1991 Feb; 61(3):279-84. PubMed ID: 2028446 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]